Table 1 Studies Used in Analysis
Study | Population | Duration (weeks) | Dose (mg/day) | Inclusion Criteria | Fasting Labs |
|---|---|---|---|---|---|
HGLB17 | Schizophrenia | 28 | 10-20 | (i) PANSS Total ≥75 (ii) PANSS Positive ≥4 (iii) CGI-S ≥4 | Yes |
HGJU18 | Schizophrenia, Schizoaffective with Comorbid Depression | 24 | 10-20 | (i) MADRS Total ≥16 (ii) MADRS item #2 ≥4 | Yes |
HGJB19 | Schizophrenia, Schizoaffective with negative Symptoms | 24 | 10-20 | (i) GAF ≤60 (ii) PANSS Negative ≥4 on at least 3 items or ≥5 on at least 2 items | No |
HGHJ20 | Schizophrenia | 28 | 10-20 | (i) BPRS ≥42 (ii) PANSS Positive ≥4 (iii) CGI-S ≥4 | Yes |
HGBG21 | Schizophrenia, Schizophreniform, Schizoaffective | 28 | 10-20 | (i) BPRS ≥42 | No |
HGGN22 | Schizophrenia, Schizoaffective | 52 | 5-20 | (i) Illness duration ≥2 yrs (ii) PANSS Positive≥4 on 2 items (iii) BPRS ≥18 | No |